Isabelle Cédrin-Durnerin, Julie Labrosse, Claire Castello Bridoux, Valérie de Buyst, Ségolène Paillet, Muriel Lubrano, Théo Cerceau, Stéphane Bouée, Bruno Salle, François Olivennes, Laetitia Jacquesson
{"title":"促黄体激素在女性不孕症治疗中的作用：法国德尔菲共识。","authors":"Isabelle Cédrin-Durnerin, Julie Labrosse, Claire Castello Bridoux, Valérie de Buyst, Ségolène Paillet, Muriel Lubrano, Théo Cerceau, Stéphane Bouée, Bruno Salle, François Olivennes, Laetitia Jacquesson","doi":"10.1007/s10815-025-03647-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To clarify clinical practice with regard to LH requirements and identify patient profiles that could benefit from luteinizing hormone (LH)-follicle-stimulating hormone co-treatment.</p><p><strong>Methods: </strong>In a Delphi survey, a scientific advisory board elaborated 28 statements on the role of luteinizing hormone (LH) in folliculogenesis (n = 7 statements), the utility of LH for follicular development prior to ovulation induction/intrauterine insemination protocols (n = 3), the utility of LH for follicular development prior to agonist or pretreated antagonist protocols in IVF (n = 6), the source and type of LH activity (n = 3), and patient profiles (n = 9). These statements were reviewed and clarified by two pilot experts. A panel of 26 French ART experts voted in two rounds. Full consensus and consensus were defined respectively as 100% and > 66% agreement. Statements could be reformulated between the two rounds of voting.</p><p><strong>Results: </strong>A full consensus or a consensus was reached for 24 of the 28 statements. All the statements concerning the pathophysiological role of LH in folliculogenesis achieved a consensus. The experts endorsed the basic science and emphasized the need to consider inter-individual variability in the clinic. Recombinant human LH was considered to optimize outcomes in a range of patient profiles: a suboptimal ovarian response to IVF stimulation, desensitization following a long agonist protocol, advanced maternal age (> 35), polymorphisms, low body mass index, and women with hypogonadotropic hypogonadism.</p><p><strong>Conclusions: </strong>This Delphi consensus from a representative group of French experts provided real-world guidance on LH's crucial importance in folliculogenesis and the patient profiles for which LH is beneficial.</p>","PeriodicalId":15246,"journal":{"name":"Journal of Assisted Reproduction and Genetics","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of luteinizing hormone in the management of female infertility: A French Delphi consensus.\",\"authors\":\"Isabelle Cédrin-Durnerin, Julie Labrosse, Claire Castello Bridoux, Valérie de Buyst, Ségolène Paillet, Muriel Lubrano, Théo Cerceau, Stéphane Bouée, Bruno Salle, François Olivennes, Laetitia Jacquesson\",\"doi\":\"10.1007/s10815-025-03647-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To clarify clinical practice with regard to LH requirements and identify patient profiles that could benefit from luteinizing hormone (LH)-follicle-stimulating hormone co-treatment.</p><p><strong>Methods: </strong>In a Delphi survey, a scientific advisory board elaborated 28 statements on the role of luteinizing hormone (LH) in folliculogenesis (n = 7 statements), the utility of LH for follicular development prior to ovulation induction/intrauterine insemination protocols (n = 3), the utility of LH for follicular development prior to agonist or pretreated antagonist protocols in IVF (n = 6), the source and type of LH activity (n = 3), and patient profiles (n = 9). These statements were reviewed and clarified by two pilot experts. A panel of 26 French ART experts voted in two rounds. Full consensus and consensus were defined respectively as 100% and > 66% agreement. Statements could be reformulated between the two rounds of voting.</p><p><strong>Results: </strong>A full consensus or a consensus was reached for 24 of the 28 statements. All the statements concerning the pathophysiological role of LH in folliculogenesis achieved a consensus. The experts endorsed the basic science and emphasized the need to consider inter-individual variability in the clinic. Recombinant human LH was considered to optimize outcomes in a range of patient profiles: a suboptimal ovarian response to IVF stimulation, desensitization following a long agonist protocol, advanced maternal age (> 35), polymorphisms, low body mass index, and women with hypogonadotropic hypogonadism.</p><p><strong>Conclusions: </strong>This Delphi consensus from a representative group of French experts provided real-world guidance on LH's crucial importance in folliculogenesis and the patient profiles for which LH is beneficial.</p>\",\"PeriodicalId\":15246,\"journal\":{\"name\":\"Journal of Assisted Reproduction and Genetics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Assisted Reproduction and Genetics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10815-025-03647-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Assisted Reproduction and Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10815-025-03647-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
The role of luteinizing hormone in the management of female infertility: A French Delphi consensus.
Purpose: To clarify clinical practice with regard to LH requirements and identify patient profiles that could benefit from luteinizing hormone (LH)-follicle-stimulating hormone co-treatment.
Methods: In a Delphi survey, a scientific advisory board elaborated 28 statements on the role of luteinizing hormone (LH) in folliculogenesis (n = 7 statements), the utility of LH for follicular development prior to ovulation induction/intrauterine insemination protocols (n = 3), the utility of LH for follicular development prior to agonist or pretreated antagonist protocols in IVF (n = 6), the source and type of LH activity (n = 3), and patient profiles (n = 9). These statements were reviewed and clarified by two pilot experts. A panel of 26 French ART experts voted in two rounds. Full consensus and consensus were defined respectively as 100% and > 66% agreement. Statements could be reformulated between the two rounds of voting.
Results: A full consensus or a consensus was reached for 24 of the 28 statements. All the statements concerning the pathophysiological role of LH in folliculogenesis achieved a consensus. The experts endorsed the basic science and emphasized the need to consider inter-individual variability in the clinic. Recombinant human LH was considered to optimize outcomes in a range of patient profiles: a suboptimal ovarian response to IVF stimulation, desensitization following a long agonist protocol, advanced maternal age (> 35), polymorphisms, low body mass index, and women with hypogonadotropic hypogonadism.
Conclusions: This Delphi consensus from a representative group of French experts provided real-world guidance on LH's crucial importance in folliculogenesis and the patient profiles for which LH is beneficial.
期刊介绍：
The Journal of Assisted Reproduction and Genetics publishes cellular, molecular, genetic, and epigenetic discoveries advancing our understanding of the biology and underlying mechanisms from gametogenesis to offspring health. Special emphasis is placed on the practice and evolution of assisted reproduction technologies (ARTs) with reference to the diagnosis and management of diseases affecting fertility. Our goal is to educate our readership in the translation of basic and clinical discoveries made from human or relevant animal models to the safe and efficacious practice of human ARTs. The scientific rigor and ethical standards embraced by the JARG editorial team ensures a broad international base of expertise guiding the marriage of contemporary clinical research paradigms with basic science discovery. JARG publishes original papers, minireviews, case reports, and opinion pieces often combined into special topic issues that will educate clinicians and scientists with interests in the mechanisms of human development that bear on the treatment of infertility and emerging innovations in human ARTs. The guiding principles of male and female reproductive health impacting pre- and post-conceptional viability and developmental potential are emphasized within the purview of human reproductive health in current and future generations of our species.
The journal is published in cooperation with the American Society for Reproductive Medicine, an organization of more than 8,000 physicians, researchers, nurses, technicians and other professionals dedicated to advancing knowledge and expertise in reproductive biology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
